CD96 and melanoma: Immunohistochemistry studies have situated CD96 as a marker of poor prognosis and immune exhaustion in HCC [48] as well as in other cancer types like melanoma [49], gastric cancer [28], and pancreatic cancer [50]; some of which also identified TIGIT as a negative prognostic marker.